The Formulation Balancing Act: Overcoming Composition And Manufacturing Challenges

By Dr. Nandu Deorkar, Senior Vice President, Research & Development – Biopharma Production

The shift toward high-concentration monoclonal antibodies (mAbs) for subcutaneous injections is revolutionizing patient care, but it comes with significant formulation and manufacturing hurdles. This article explores how the right mix of excipients, stabilizers and buffers can minimize injection-site pain, while single-use technologies secure the fluid path to minimize contamination risks. Learn more about managing critical formulation challenges to pave the way for more patient-friendly therapies.